Skip to content

Journal · Urologic oncology · Updated 20 November 2026

Prostate Cancer and Prostatic Diseases

Read Prostate Cancer and Prostatic Diseases articles on DeepDyve. No university library needed.

Prostate Cancer and Prostatic Diseases has published since 1997 and covers prostate cancer and other prostate conditions, from drug treatment and screening with imaging to surgery for an enlarged prostate. Springer Nature publishes it. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including Springer Nature.

Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.

Personal plans aren’t for business use. Reading for work? See Enterprise.

Cover of Prostate Cancer and Prostatic Diseases
November 2026 issue

Prostate Cancer and Prostatic Diseases at a glance

Full title
Prostate Cancer and Prostatic Diseases
Abbreviation (NLM)
Prostate Cancer Prostatic Dis
Publisher
Springer Nature
Print ISSN
1365-7852
Online ISSN (eISSN)
1476-5608
First published
1997
Subjects
Neoplasms, Urology
Access model
Hybrid (34% free to read in 2026)

Ways to access Prostate Cancer and Prostatic Diseases

34% of the articles Prostate Cancer and Prostatic Diseases published from January 1 to November 19, 2026 are open access and free to read. For the rest, look for the authors’ manuscript, check a library, or read them on DeepDyve.

  1. Open access articles. 34% of Prostate Cancer and Prostatic Diseases articles published from January 1 to November 19, 2026 carry a Creative Commons license, per Crossref, and are free to read. They’re marked “Open access” below.
  2. The authors’ accepted manuscript. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central.
  3. NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
  4. A library. Your university, hospital or public library may subscribe to Prostate Cancer and Prostatic Diseases. Check its journal list and whether it offers remote access.
  5. DeepDyve. Read Prostate Cancer and Prostatic Diseases articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.

Sources: Springer Nature self-archiving policy; NIH Public Access Policy; open access share from Crossref license data.

Recent Prostate Cancer and Prostatic Diseases research worth reading

Published January to June 2026. Summaries describe what the authors report.

  1. Open accessProstate cancer · Drug treatment

    Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study

    Drawing on records of 424 patients at 29 cancer centres in 9 countries, the authors report a median 31.8 months on enzalutamide for metastatic hormone-sensitive prostate cancer, with 76% reaching a 90% drop in PSA and grade 3–4 adverse events in about 10%.

    Büttner et al. · Prostate Cancer and Prostatic Diseases, published online January 8, 2026 · DOI 10.1038/s41391-025-01067-3

  2. LitStreamProstate cancer · Bone health

    Risk of bone fractures in patients with prostate cancer treated with maximal androgen blockade therapy: a systematic literature review and meta-analysis

    In a systematic review and meta-analysis of 17 studies with 16162 patients, Saporita and colleagues report that adding an androgen receptor pathway inhibitor to androgen deprivation therapy significantly increased fracture risk (pooled odds ratios 1.5 to 2.4), with no difference between inhibitors.

    Saporita et al. · Prostate Cancer and Prostatic Diseases, published online January 26, 2026 · DOI 10.1038/s41391-026-01077-9

  3. LitStreamBenign prostatic hyperplasia · Devices

    Zenflow spring system for benign prostatic hyperplasia – 24 month outcomes of the ZEST pilot studies

    Combining three single-arm prospective pilot studies of 72 men, Gilling and colleagues report that the Zenflow Spring System was implanted in all participants with no perioperative serious adverse events, and that symptom scores improved 49% at 3 months and 48% at 24 months.

    Gilling et al. · Prostate Cancer and Prostatic Diseases, published online June 9, 2026 · DOI 10.1038/s41391-026-01126-3

  4. LitStreamProstate cancer · Surgery

    Radical prostatectomy without prior biopsy: an initial decision-making algorithm based on PSMA PET/mpMRI

    Of 150 patients prospectively enrolled under a PSMA PET/CT and MRI decision algorithm, Li and colleagues report that 120 underwent radical prostatectomy without prior biopsy, with clinically significant cancer detected in 100% and no complications above Clavien-Dindo grade II.

    Li et al. · Prostate Cancer and Prostatic Diseases, published online January 31, 2026 · DOI 10.1038/s41391-026-01081-z

  5. LitStreamProstate cancer · Diagnostic imaging

    Comparative diagnostic accuracy of multiparametric-MRI and Micro-ultrasound for clinically significant prostate cancer—a bivariate meta-analysis of prospective studies

    In a systematic review and meta-analysis of eight prospective studies with 2626 patients, Garcia-Becerra and colleagues report that micro-ultrasound had sensitivity similar to multiparametric MRI for clinically significant prostate cancer (0.87 versus 0.88), while MRI had significantly higher specificity.

    Garcia-Becerra et al. · Prostate Cancer and Prostatic Diseases, published online February 3, 2026 · DOI 10.1038/s41391-026-01079-7

See every Prostate Cancer and Prostatic Diseases article on DeepDyve

Questions about Prostate Cancer and Prostatic Diseases

How can I read Prostate Cancer and Prostatic Diseases articles without a subscription?

34% of Prostate Cancer and Prostatic Diseases articles published from January 1 to November 19, 2026 are open access and free to read. For subscription articles, Springer Nature lets authors make their accepted manuscript public 6 months after publication, on a personal website or in a repository such as PubMed Central. Your library may also subscribe. DeepDyve lets you read Prostate Cancer and Prostatic Diseases articles online for $59 a month or $499 a year after a free first month.

What is the abbreviation for Prostate Cancer and Prostatic Diseases?

Prostate Cancer and Prostatic Diseases’ NLM (PubMed) abbreviation is Prostate Cancer Prostatic Dis.

What is the ISSN of Prostate Cancer and Prostatic Diseases?

The print ISSN is 1365-7852 and the online ISSN is 1476-5608.

Is Prostate Cancer and Prostatic Diseases open access?

Prostate Cancer and Prostatic Diseases is a hybrid journal: most articles are published under the subscription model, and authors can choose to publish open access. From January 1 to November 19, 2026, 28 of 83 Prostate Cancer and Prostatic Diseases articles (34%) carry a Creative Commons license, per Crossref.

Prostate Cancer and Prostatic Diseases articles on DeepDyve are licensed from Springer Nature. Journal facts as of 20 November 2026.

Start reading Prostate Cancer and Prostatic Diseases today

One month free, then less than $2 a day. Prostate Cancer and Prostatic Diseases, plus millions of articles from thousands of journals.

Start free month

Like this: